Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

TLR-targeted therapies show promise in cancer treatment by helping destroy tumors.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

TTD patients don't have a higher skin cancer risk because their main issue is with transcription, not DNA repair.

KRTAP2-3 could help predict cancer recurrence by identifying specific cancer cells.

Tumor-targeted drug carriers can improve chemotherapy precision and reduce side effects.

Hair loss is a common side effect of hormone treatments for cancer.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

A man got six skin cancers within a year after a cell transplant for leukemia but was cancer-free 32 months later; skin checks are important post-transplant.

Flow cytometry was effective in diagnosing metastatic breast cancer in a bone marrow sample.

Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.

Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Ovarian function was similar in both treatment groups, but both caused excessive hair growth.

Combining tacrolimus with excimer light is more effective for treating alopecia areata than using excimer light alone.

Kang-ai injection with platinum-based chemotherapy improves tumor response and immune function while reducing side effects in advanced lung cancer.

JAK inhibitors may help treat alopecia areata by reversing hair loss.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.

Docetaxel, a chemotherapy drug, was reported to cause psoriasis in a patient for the first time.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

Biobran MGN-3 reduces chemotherapy side effects and improves quality of life for breast cancer patients.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.

A medication for skin rash also unexpectedly treated hair loss in a patient.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.